A primitive cell origin for B-cell precursor ALL?
A stem cell origin has been described for both acute and chronic myelogenous leukemias. In contrast, childhood B-cell precursor acute lymphoblastic leukemia (ALL) is thought to arise in committed B-lineage cells. Recently described in vitro and in vivo model systems that support the proliferation and expansion of ALL cells have provided new tools to investigate the cellular targets for the origin of this malignancy. Evidence suggests that some subtypes of childhood ALL have a primitive cell origin and share many immunophenotypic characteristics with normal progenitor cells. These leukemic stem cells may be resistant to current therapeutic strategies designed to kill the bulk ALL cell population and subsequent relapses may arise from this population. More precise definition of these ALL stem cells through combined analyses of antigen expression, genetic lesions, and functionality is essential for the development of more effective, targeted therapeutic strategies.
Cox
C V
CV
Bristol Institute for Transfusion Sciences, University of Bristol BS10 5ND, UK.
Blair
A
A
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology*; D002051:Burkitt Lymphoma / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D049109:Cell Proliferation; D015973:Gene Expression Regulation, Leukemic / Q000276:immunology*; D006801:Humans; D014411:Neoplastic Stem Cells / Q000276:immunology* / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D012008:Recurrence
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor